PubCo Insight Institutional & Sector Brief: Covering BioCardia, Inc. (Nasdaq: BCDA) following its 2026-11-12 Form 8-K. Prepared for PubCo Insight’s verified vault of 22,361 Active Microcap Traders, Prop Desks & Family Offices.
BioCardia, Inc. (Nasdaq: $BCDA, market capitalization ~$18.0M), led by Peter Altman, operates across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization. Primary exchange and regulatory disclosures following its 2026-11-12 Form 8-K frame investor diligence around balance-sheet discipline and near-term execution.
BCDA price and volume, last 90 days. Source: Yahoo Finance.
2. Institutional & Family Office Peer Comparison ($PCSA, $CRMD, and $FBIO)
Across our institutional and active small-cap allocator screens benchmarking $BCDA against $PCSA, $CRMD, and $FBIO, three factors stand out:
Valuation & Capital Structure Positioning: At a ~$18.0M market capitalization, $BCDA trades at a distinct valuation multiple relative to sector comparables ($PCSA, $CRMD, and $FBIO) competing for the same specialist capital.
Institutional & Family Office Overlap: Inside Pulse IR’s 22,361-contact verified investor vault, 165 microcap funds, RIAs, and family offices and 3,120 active small-cap traders track $PCSA, $CRMD, and $FBIO.
Catalyst & Liquidity Alignment: Pairing clean primary-source research citations with direct institutional and family-office introductions helps bridge liquidity gaps ahead of upcoming operating milestones.
Free Public-Company AI & Investor Search Visibility Report
BioCardia, Inc. ($BCDA) Investor Search & Diligence Audit
35 / 100
Visibility Score
Why This Costs $BCDA Buyers & Volume: Before retail traders, family offices, or microcap funds buy a single share of $BCDA, over 70% run a 30-second search across ChatGPT, Perplexity Finance, and TradingView. When prospective investors cannot find clean, current SEC figures or hit stale third-party data, they skip out, do not invest, and buy a peer instead. Here is what investors currently see when they search BioCardia, Inc.:
Investor Search Surface
Score
Where Prospective Buyers Are Dropping Off
ChatGPT & OpenAI Search
32/100
Missing root /llms.txt manifest and structured IR schema; surfaces stale baseline summaries instead of recent $BCDA SEC filings.
Perplexity Finance & Citations
39/100
Pulls fragmented quote-scraper snippets instead of verified SEC EDGAR operating milestones and peer valuation context for $BCDA.
TradingView, FactSet & Sector Screens
34/100
$BCDA is omitted from AI discovery screens covering clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization due to unindexed entity and FAQPage metadata.
Turnkey Cleanup & Investor Distribution Package for BioCardia, Inc.: Pulse IR fixes how ChatGPT, Perplexity, TradingView, FactSet, Wikidata, and your IR page display $BCDA directly from your SEC filings (requiring zero hours from your team), and then distributes your verified story to our 22,361 active microcap traders and 165 family offices and funds tracking your sector. To claim this report and review our turnkey package with CEO Brad Listermann, visit pulseir.co or call 424-250-0042.
Compiled by the PubCo Insight Editorial & Institutional Desk from primary SEC EDGAR disclosures and market data. Published for informational and research purposes only, not investment advice or a buy/sell recommendation.